The original human insulin-based products, such as NPH insulin, had suboptimal pharmacokinetic (PK) profiles, characterised by inappropriate peaks of action coupled with high variability from injection to injection, both of which can lead to hypoglycaemia and oblige twice-daily dosing (1,5,6). Here, INS is linked to Hypoglycemia.